Celsius Therapeutics
Acquired
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- celsiustx.com
- Total Funding
- $148.0M
- Last Round
- $83.0M Series BMar 2022
About
Celsius Therapeutics was a biotechnology company that leveraged single-cell RNA sequencing and genomic analysis to identify novel drug targets and develop precision medicines for complex diseases including autoimmunity and cancer. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company built a human tissue-based platform combining scRNA-seq with machine learning to characterize disease biology at the cellular level. Celsius was acquired by AbbVie in June 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account